Navigation Links
Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
Date:6/28/2014

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

"Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies," said Takayuki Yoshino of the National Cancer Centre Hospital East in Chiba, Japan, lead author of the phase III RECOURSE trial. "The RECOURSE study shows that TAS-102 improves overall survival in these patients compared to placebo. I believe that this agent will become one of the standards of care in the refractory setting of metastatic colorectal cancer in Japan and worldwide."

TAS-102 is a novel nucleoside anti-tumour agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD is the active component of TAS-102 and is directly incorporated into cancer DNA, leading to DNA dysfunction. However, when FTD is taken orally it is largely degraded to an inactive form. TPI prevents the degradation of FTD. This mechanism of action is different to that of fluoropyrimidine, oxaliplatin and irinotecan.

The phase II trial of TAS-102 had found an overall survival benefit in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine 5-fluorouracil (5-FU), irinotecan and oxaliplatin.[1]

The current RECOURSE study was a global phase III trial conducted in 13 countries at 114 centres. Patients had metastatic colorectal cancer refractory to all standard therapies including fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab for patients with wild-type KRAS tumours. Patients were randomised 2:1 to TAS-102 (534 patients) or placebo (266 patients). The primary endpoint was overall survival.

The researchers found that TAS-102 prolonged overall survival compared to placebo (hazard ratio 0.68): median overall survival was 7.1 months for TAS-102 and 5.3 months for placebo. TAS-102 also improved progression-free survival compared to placebo (hazard ratio 0.48), which was a secondary endpoint. Yoshino said: "We found a statistically significant difference in overall and progression-free survival, and a clinically meaningful improvement."

"TAS-102 has a mild safety profile and the most common side-effect is hematologic toxicity including neutropenia. Patients with metastatic colorectal cancer refractory to standard therapies now have a strong treatment option."

Commenting on the data, ESMO spokesperson Jean Yves Douillard, professor of medical oncology, Institut de Cancrologie de l'Ouest (ICO) Ren Gauducheau, Saint-Herblain, France, said: "The phase III trial of TAS-102 is a global study and confirms the results of the phase II study in Japanese patients, whose response to fluoropyrimidine is slightly different to patients in Europe and the US. It is good to know that the magnitude of benefit shown in the smaller phase II trial is confirmed in the larger phase III trial and that the results apply to Asians and Caucasians alike."

TAS-102 is a combination of two components. The tipiracil hydrochloride (TPI) prevents degradation of trifluridine (FTD) and also has angiogenic activity. "This is probably why TAS-102 is effective in classical fluoropyrimidine 5-fluorouracil (5-FU) resistant patients. The drug is very promising, tolerance is good and it is manageable with supportive care."

Douillard concluded: "In RECOURSE, TAS-102 was tested in patients who had received all types of chemotherapy available for colorectal cancer. I would probably move this drug into an earlier line of treatment and I would also combine it with either irinotecan or oxaliplatin."


'/>"/>

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Improved Stem Cell Line May Avoid Tumor Risk: Study
2. Staging and risk stratification of thyroid cancer improved with SPECT/CT
3. Reported increase in older adult fall deaths due to improved coding
4. Ketamine improved bipolar depression within minutes
5. Exercise program improved health of lung transplant patients and cut cardiovascular risk
6. GMCSF treatment associated with improved cognition in cancer patients
7. PaleoMeal Organic Whey Protein Formula Improved According to Rockwell Nutrition
8. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
9. Expanding Medicaid to low-income adults leads to improved health, fewer deaths
10. Is Improved Vaccine Causing Whooping Cough Outbreaks?
11. HCOs find risks & opportunities in quest for reduced costs & improved quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology: